SIGLEC1 and myeloid sarcoma: In summary, our data indicate that type I interferons or SIGLEC1 expressing cells in the peripheral blood do not play a major role in the pathogenesis of most patients with stable NMOSD or MS, however SIGLEC1+ myeloid cells in the brain are present in active inflammatory MS lesions as well as in other inflammatory neurological diseases of the CNS.